These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 17549311)

  • 1. Improved visualisation of high-molecular-weight von Willebrand factor multimers.
    John Bowen D; Bowley SJ
    Thromb Haemost; 2007 Jun; 97(6):1051-2. PubMed ID: 17549311
    [No Abstract]   [Full Text] [Related]  

  • 2. An optimized electrophoresis method for high-resolution imaging of von-Willebrand multimers.
    Weiss DR; Thiel C; Strasser EF; Zimmermann R; Eckstein R
    Thromb Haemost; 2008 Nov; 100(5):949-51. PubMed ID: 18989543
    [No Abstract]   [Full Text] [Related]  

  • 3. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rapid method for the diagnosis of von Willebrand's disease subtypes by the clinical laboratory.
    Slaughter TF; Parker JK; Greenberg CS
    Arch Pathol Lab Med; 1995 Feb; 119(2):148-52. PubMed ID: 7848061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Collection and transport of samples for laboratory testing in von Willebrand's disease (VWD): time for a reappraisal?
    Favaloro EJ; Nair SC; Forsyth CJ
    Thromb Haemost; 2001 Dec; 86(6):1589-90. PubMed ID: 11776337
    [No Abstract]   [Full Text] [Related]  

  • 6. von Willebrand factor multimers: their demonstration and significance.
    McLellan DS; Webb C
    Med Lab Sci; 1988 Oct; 45(4):358-69. PubMed ID: 3077427
    [No Abstract]   [Full Text] [Related]  

  • 7. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory and molecular characteristics of recessive von Willebrand disease type 2C (2A subtype IIC) of variable severity due to homozygous or double heterozygous mutations in the D1 and D2 domains.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):111-8. PubMed ID: 19506357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunostaining of von Willebrand factor multimers on agarose gels and nitrocellulose filters.
    Perutelli P
    Haematologica; 2002 Feb; 87(2):223-4. PubMed ID: 11836176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autosomal dominant von Willebrand disease type 2M.
    Hermans C; Batlle J
    Acta Haematol; 2009; 121(2-3):139-44. PubMed ID: 19506360
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visualization of the multimeric structure of von Willebrand factor using a peroxidase-conjugated second antibody.
    Zaleski A; Henriksen RA
    J Lab Clin Med; 1986 Feb; 107(2):172-5. PubMed ID: 3511161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Suspected von Willebrand disease--how to proceed?].
    Thorsen S; Ingerslev J
    Ugeskr Laeger; 2002 Feb; 164(6):783. PubMed ID: 11851189
    [No Abstract]   [Full Text] [Related]  

  • 14. Two-dimensional analysis of the structure of human von Willebrand factor.
    Perutelli P; Catellani S; Mori PG
    Haematologica; 1998 Sep; 83(9):859-60. PubMed ID: 9825587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of a new automated method for von Willebrand factor antigen measurement: the STA-Liatest vWF].
    Veyradier A; Fressinaud E; Sigaud M; Wolf M; Meyer D
    Ann Biol Clin (Paris); 1999 May; 57(3):364-8. PubMed ID: 10377492
    [No Abstract]   [Full Text] [Related]  

  • 16. A modified SDS agarose gel method for determining factor VIII von Willebrand factor multimers using commercially available reagents.
    Miller MA; Palascak JE; Thompson MR; Martelo OJ
    Thromb Res; 1985 Sep; 39(6):777-80. PubMed ID: 3936225
    [No Abstract]   [Full Text] [Related]  

  • 17. Is the activated partial thromboplastin time suitable to screen for von Willebrand factor deficiencies?
    Lippi G; Franchini M; Poli G; Salvagno GL; Montagnana M; Guidi GC
    Blood Coagul Fibrinolysis; 2007 Jun; 18(4):361-4. PubMed ID: 17473578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Method of determining von Willebrand factor activity].
    Papaian LP
    Lab Delo; 1982; (5):275-8. PubMed ID: 6178881
    [No Abstract]   [Full Text] [Related]  

  • 19. Decreased clearance of von Willebrand factor in a patient with type 2B von Willebrand disease following development of immune thrombocytopenia.
    Wang ZJ; Onwuzurike N; Callaghan MU; Rajpurkar M; Chitlur M; Lusher JM
    Pediatr Blood Cancer; 2008 Sep; 51(3):416-8. PubMed ID: 18493997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of a novel mutation in the von Willebrand factor propeptide in a distinct subtype of recessive von Willebrand disease.
    Lanke E; Kristoffersson AC; Philips M; Holmberg L; Lethagen S
    Thromb Haemost; 2008 Aug; 100(2):211-6. PubMed ID: 18690339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.